Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus

Abstract

A recent study showed transcriptional levels of interferon-inducible chemokines in peripheral blood cells were associated with disease activity and organ damage in systemic lupus erythematosus, and may be useful in monitoring disease activity and prognosis. Our objective was to evaluate the capacity of atorvastatin to reduce plasma levels of interferon-regulated chemokines (CCL2, CCL3 and CXCL9) and to study the correlation between these chemokines and disease activity in patients with systemic lupus erythematosus. Eighty-eight female patients with systemic lupus erythematosus were divided into two groups: 64 receiving 20 mg/day of atorvastatin (intervention group) and 24 without atorvastatin (control group). All patients were followed for 8 weeks. At baseline and after 8 weeks laboratory tests were performed for all patients. Plasma levels of chemokines were measured by ELISA using commercial kits (DuoSet, R&D Systems, Minneapolis, USA). In a univariate analysis we found correlation between CCL2, CCL3 and CXCL9 plasma levels and SLEDAI score. In the intervention group we observed a significant decrease in CXCL9 plasma levels comparing baseline and levels at the end of the study (p = 0.04); however, no differences were observed regarding CCL2 or CCL3 plasma levels in this study. No significant difference was observed in the plasma levels of these chemokines in the control group. We conclude that treatment with atorvastatin was associated with a significant decrease in the plasma levels of CXCL9 in patients with systemic lupus erythematosus. As the plasma levels of CXCL9 correlated with the SLEDAI score, we ask whether reducing levels of this chemokine could help to control systemic lupus erythematosus activity. Lupus (2010) 19, 927—934.

Keywords

atorvastatin chemokine systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Baggiolino M. Chemokines and leukocyte traffic. Nature 1998; 392: 565-568.

Eriksson C. , Eneslätt K. , Ivanoff J. , Rantapää-Dahlqvist S. , Sundqvist K-G . Abnormal expression of chemokine receptors on T-cells from patients with systemic lupus erythematosus. Lupus 2003; 12: 766-774.

Robinson E. , Keystone EC , Schall TJ , Gillett N. , Fish EN Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1α production by synovial T Cells . Clin Exp Immunol 1995; 101: 398-407.

Hasegawa M. , Sato S. , Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α) and MIP-1β) in patients with systemic sclerosis: MCP-1 and MIP-1á may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999 ; 117: 159-165.

Vilá LM , Molina MJ , Mayor AM , Cruz JJ , Rios-Olivares E. , Rios Z. Association of serum MIP-1 alpha, MIP-1 beta, and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus. Clin Rheumatol 2007; 26: 718-722.

Bauer JW , Baechler EC , Petri M. , et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006; 3: e491.

Lit LCW , Wong CK , Tam LS , Li EKM , Lam CW Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus . Ann Rheum Dis 2006; 65: 209-215.

Fu Q. , Chen X. , Cui H. , et al. Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients. Arthritis Res Ther 2008; 10: R112.

Noris M. , Bernasconi S. , Casiraghi F. , et al. Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab Invest 1995; 73: 804-809.

10.

Wada T. , Yokoyama H. , Su SB , et al. Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 1996; 49: 761-767.

11.

Meller S. , Winterberg F. , Gilliet M. , et al. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: An amplification cycle triggering cutaneous lupus erythematosus . Arthritis Rheum 2005; 52: 1504-1516.

12.

Wenzel J. , Worenkamper E. , Freutel S. , et al. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol 2005; 205: 435-442.

13.

Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109: 39-43.

14.

Kwak B. , Mulhaupt F. , Myit S. , Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399-1402.

15.

Mason JC Statins and their role in vascular protection. Clin Sci 2003; 105: 251-266.

16.

Ascer E. , Bertolami MC , Venturinelli ML , et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 2004; 177: 161-166.

17.

Meroni PL , Luzzana C. , Ventura D. Anti-inflammatory and immunomodulating properties of statins An additional tool for the therapeutic approach of systemic autoimmune disease?. Clin Rev Allerg Immunol 2002; 23: 263-277.

18.

Leung BP , Sattar N. , Crilly A. , et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003; 170: 1524-1530.

19.

Ferreira GA , Navarro TP , Telles RW , Andrade LEC , Sato EI Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology 2007; 46: 1560-1565.

20.

Hochberg MG Update the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.

21.

Bombardier C. , Gladman DD , Urowitz MB , Caron D. , Chang CH Derivation of the SLEDAI: a disease activity index for lupus patients: the committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640.

22.

Gladman DD , Urowitz MB , Goldsmith CH , et al. The reliability of the Systemic Lupus International Collaborating Clinics/ American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 809-813.

23.

Anger T. , Pohle FK , Kandler L. , et al. VAP-1, Eotaxin3 and MIG as potential atherosclerotic triggers of severe calcified and stenotic human aortic valves: effects of statins. Exp Mol Pathol 2007; 83: 435-442.

24.

Mach F. , Sauty A. , Iarossi AS , et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest 1999; 104: 1041-1050.

25.

Sheikh AM , Ochi H. , Manabe A. , Masuda J. Lysophosphatidylcholine posttranscriptionally inhibits interferon-gamma-induced IP-10, Mig and ITac expression in endothelial cells. Cardiovasc Res 2005; 65: 263-271.

26.

Moore KJ , Wada T. , Barbee SD , Kelley VR Gene transfer of RANTES elicits autoimmune renal injury in MRL-Fas(1pr) mice . Kidney Int 1998; 53: 1631-1641.

27.

Stahl RA , Thaiss F. , Disser M. , Helmchen U. , Hora K. , Schlondorff D. Increased expression of monocyte chemoattractant protein-1 in anti-thymocyte antibody-induced glomerulonephritis. Kidney Int 1993; 44: 1036-1047.

28.

Chan RW , Tam LS , Li EK , et al. Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis Rheum 2003; 48: 1326-1331.

29.

Enghard P. , Humrich JY , Rudolph B. , et al. CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients. Arthritis Rheum 2009; 60: 199-206.

30.

Yajima N. , Kasama T. , Isozaki T. , et al. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations. Arthritis Rheum 2005; 52: 1670-1675.

31.

Grip O. , Janciauskiene S. Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn’s Disease. PLoS ONE 2009; 4: e5263.